Enlivex Therapeutics Ltd.
NASDAQ:ENLVBiotechnology
Healthcare
$4.26 +2.67%
+$0.19 today
- Market cap
- $71.70M
- Beta
- 1.52
- P/E (TTM)
- 0.0
- EPS (TTM)
- $407.81
52W Low $6.42High $31.50
Volume 0.06M
Average 0.44M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$15.00M
FY 2025 · Annual
Net Income
$1.24B
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 546K | 777K | 835K | 545K | 332K |
| Gross Profit | (546K) | (777K) | (835K) | (545K) | (332K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.88M | 18.69M | 19.24M | 10.13M | 8.92M |
| Selling, General & Admin | 6.24M | 6.7M | 6.14M | 4.91M | 5.69M |
| Operating Expenses | 19.29M | 25.8M | 29.4M | 14.99M | 14.67M |
| Depreciation & Amortization | 546K | 777K | 835K | 545K | 332K |
| EBITDA | (18.74M) | (25.02M) | (28.22M) | (14.47M) | (14.67M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.29M) | (25.8M) | (29.4M) | (15.54M) | (15M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 120K | 835K | 1.57M | 1.07M | 792K |
| Interest Expense | 328K | 5.26M | 14K | 13K | 13K |
| Other Income / Expenses | 4.82M | (5.26M) | 327K | 522K | 1.63B |
| Income Before Tax | (14.47M) | (31.06M) | (29.07M) | (15.01M) | 1.62B |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 382.65M |
| Net Income | (14.47M) | (31.06M) | (29.07M) | (15.01M) | 1.24B |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (8.10) | (34.65) | (23.40) | (10.95) | 405.60 |
| EPS (Diluted) | (8.10) | (34.65) | (23.40) | (10.95) | 382.20 |
| 1.19M | 1.23M | 1.24M | 1.37M | 3.05M | |
| 1.19M | 1.23M | 1.24M | 1.37M | 3.23M |
ENLV Earnings Waterfall · TTM
NASDAQ:ENLV · Revenue to Net Income
Key Ratios
EPS$381.90
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.0
P/S Ratio0.0
Analysis
$0 of revenue converted into $1.2B of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $381.90, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Jul 20, 2026 | |
| 6-K | 6-K filing | Jul 13, 2026 | |
| 6-K | 6-K filing | Jul 7, 2026 | |
| 6-K | 6-K filing | Jun 24, 2026 | |
| 6-K | 6-K filing | Jun 22, 2026 |
How much revenue does ENLV generate?
Enlivex Therapeutics Ltd. (ENLV) reported $0.00 of revenue in fiscal 2025.
Is ENLV profitable?
Enlivex Therapeutics Ltd. (ENLV) reported $1.24B of net income.
Continue the stock analysis
Jump to another research area for this company.